Aspira Women’s Health (NASDAQ:AWH) Receives New Coverage from Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a report published on Tuesday morning. The firm issued a hold rating on the stock.

Separately, Alliance Global Partners lowered their target price on Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.

View Our Latest Research Report on Aspira Women’s Health

Aspira Women’s Health Price Performance

Shares of AWH opened at $0.75 on Tuesday. The firm’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.84. The company has a market capitalization of $9.36 million, a P/E ratio of -0.52 and a beta of 1.47. Aspira Women’s Health has a 1-year low of $0.74 and a 1-year high of $6.01.

Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last released its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period in the prior year, the business posted ($0.28) EPS. On average, equities analysts anticipate that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its holdings in Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 43.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 179,371 shares of the company’s stock after purchasing an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.73% of Aspira Women’s Health worth $732,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.19% of the stock is owned by institutional investors and hedge funds.

About Aspira Women’s Health

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.

Further Reading